Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 First case of DRESS (drug reaction with eosinophilia and systemic symptoms) associated with voxelotor.

Literature DB >> 34478170

First case of DRESS (drug reaction with eosinophilia and systemic symptoms) associated with voxelotor.

Matthew Lee¹, Thomas Stringer², Jack Jacob³, Elana M Friedman⁴, Caterina Minniti¹, Henny H Billett¹, Susanna A Curtis¹.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2021 PMID： 34478170 PMCID： PMC9316384 DOI： 10.1002/ajh.26342

Source DB: PubMed Journal: Am J Hematol ISSN： 0361-8609 Impact factor: 13.265

× No keyword cloud information.

10 in total

1. Population estimates of sickle cell disease in the U.S.

Authors: Kathryn L Hassell
Journal: Am J Prev Med Date: 2010-04 Impact factor: 5.043

Review 2. Sickle Cell Disease.

Authors: Frédéric B Piel; Martin H Steinberg; David C Rees
Journal: N Engl J Med Date: 2017-04-20 Impact factor: 91.245

3. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.

Authors: Elliott Vichinsky; Carolyn C Hoppe; Kenneth I Ataga; Russell E Ware; Videlis Nduba; Amal El-Beshlawy; Hoda Hassab; Maureen M Achebe; Salam Alkindi; R Clark Brown; David L Diuguid; Paul Telfer; Dimitris A Tsitsikas; Ashraf Elghandour; Victor R Gordeuk; Julie Kanter; Miguel R Abboud; Joshua Lehrer-Graiwer; Margaret Tonda; Allison Intondi; Barbara Tong; Jo Howard
Journal: N Engl J Med Date: 2019-06-14 Impact factor: 91.245

4. A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease.

Authors: Jo Howard; Claire Jane Hemmaway; Paul Telfer; D Mark Layton; John Porter; Moji Awogbade; Timothy Mant; Daniel D Gretler; Kobina Dufu; Athiwat Hutchaleelaha; Mira Patel; Vincent Siu; Sandra Dixon; Noel Landsman; Margaret Tonda; Joshua Lehrer-Graiwer
Journal: Blood Date: 2019-01-17 Impact factor: 22.113

5. GBT440 improves red blood cell deformability and reduces viscosity of sickle cell blood under deoxygenated conditions.

Authors: Kobina Dufu; Mira Patel; Donna Oksenberg; Pedro Cabrales
Journal: Clin Hemorheol Microcirc Date: 2018 Impact factor: 2.375

1 in total

Review 1. Comparing the Safety and Efficacy of L-Glutamine, Voxelotor, and Crizanlizumab for Reducing the Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease: A Systematic Review.

Authors: Maurice H Dick; Arowa Abdelgadir; Vaishnavi Vijaya Kulkarni; Hamna Akram; Abanti Chatterjee; Sushil Pokhrel; Safeera Khan
Journal: Cureus Date: 2022-05-11

1 in total

First case of DRESS (drug reaction with eosinophilia and systemic symptoms) associated with voxelotor.

1. Population estimates of sickle cell disease in the U.S.

Review 2. Sickle Cell Disease.

3. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.

4. A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease.

5. GBT440 improves red blood cell deformability and reduces viscosity of sickle cell blood under deoxygenated conditions.

Review 6. Drug reaction with eosinophilia and systemic symptoms (DRESS): incidence, pathogenesis and management.

Review 7. The DRESS syndrome: a literature review.

8. Severe Vaso-Occlusive Episodes Associated with Use of Systemic Corticosteroids in Patients with Sickle Cell Disease.

9. Voxelotor: A Novel Treatment for Sickle Cell Disease.

10. Recurrence of drug-induced reactions in DRESS patients.

Review 1. Comparing the Safety and Efficacy of L-Glutamine, Voxelotor, and Crizanlizumab for Reducing the Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease: A Systematic Review.